The only circumstances where compounding semaglutide or tirzepatide may be permissible are: True allergy to a specific inactive ingredient in the FDA-approved version, documented with allergy testing and medical records Documented medical need for a different concentration not commercially available, with clear clinical justification Specific patient population requiring dosage form modification , such as pediatric use, with proper medical justification Healthcare providers must document medical necessity with extensive clinical evidence
Working With HR Your HR department can help clarify coverage questions, explain the appeals process for your specific plan, and potentially advocate for coverage decisions
For Orange County patients, the appeal of Ozempic often comes down to practicality
Eat well
Subclinical hypothyroidism (elevated TSH with normal free T4) is also not a contraindication, though optimisation of thyroid function before initiating weight management therapy is often advisable
Starting at a low dose of 0.25 mg in the first week is a crucial step to minimize potential gastrointestinal side effects that many patients experience when beginning treatment with semaglutide GLP-1
